Xconomy Xchange: The Icos Impact
Tuesday, November 27, 2012 at 5:00 PM (PST)
Seattle, United States
Icos was once the great hope for Seattle biotech. Founded in 1990 with investment from Bill Gates and inspirational leadership from George Rathmann, it went on over the next 15 years to assemble a team of 700 employees and create a $1 billion molecule. For a while, it looked like it would survive as the only big, independent, profitable biotech company in the Seattle area. The story didn't unfold that way, as Eli Lilly bought the company for $2.3 billion in 2007 and gave pink slips to most of the local workforce. Some Icos alumni stayed on to help build CMC Biologics, and some left the region for new opportunities. But many talented scientists and businesspeople have stayed in the Northwest, building the next generation of Seattle life sciences companies. Come join Xconomy on November 27 as we bring together some of the leading Icosahedrons (yes, there's a trivia question there) for a lively evening of war stories, networking, and thinking about what's ahead for Seattle biotech.
Stephanie Florio, Scientist, Infectious Disease Research Institute
Mike Gallatin, Senior Advisor, Frazier Healthcare Ventures
Patrick Gray, Scientific Fellow, Omeros
Mila Lobanova, VP of Finance and Operations, Blaze Bioscience
Johnny Stine, Founder, North Coast Biologics
Cliff Stocks, CEO, Theraclone Sciences
Susan Sullivan, Vice President of Project Management, CMC Biologics
Gary Wilcox, CEO, Cocrystal Discovery
Albert Yu, Vice President of Clinical Development, Omeros
Registration & Networking: 5:00 - 6:00 pm
Program: 6:00 - 6:35 pm
Networking reception: 6:35 - 8:00 pm
Tickets are transferable but not refundable.
To inquire about press registration, email email@example.com.
Alexandria Real Estate Equities
BDO • Christensen O’Connor Johnson Kindness • Cooley
Davis Wright Tremaine • Fenwick & West • Graham & Dunn • Institute for Systems Biology
Kauffman Foundation • Kilpatrick Townsend • Puget Sound Blood Center
VENTURE CAPITAL MEMBERS
ARCH Venture Partners • WRF Capital